Group Submits Duchenne Muscular Dystrophy Guidance, Hoping To Direct FDA Policy
Parent Project Muscular Dystrophy’s proposed guidance gives detail on biomarkers and clinical trial designs for the beleaguered field, but most importantly addresses benefit-risk assessment – which is FDA’s underlying ambition for the patient-focused drug development initiative.
You may also be interested in...
After conducting 24 disease-focused meetings in five years, FDA moving to next phase of patient interaction under new user fee cycle.
Patient Engagement Collaborative expected to invite stakeholders to discuss how patient interaction with FDA can improve.
FDA floats idea of central office to coordinate patient engagement for symbolic as well as practical reasons.